Where can I find the actual financial results for AbbVie's fourth quarter and full year 2025?

The actual financial results are detailed in the press release issued by AbbVie on February 4, 2026, which is furnished as Exhibit 99.1 to this 8-K filing. Investors should review this exhibit for specific figures and commentary.

What is the significance of this 8-K filing?

This 8-K filing is primarily a procedural step to officially submit AbbVie's Q4 and full-year 2025 financial results, as announced in their press release, to the U.S. Securities and Exchange Commission (SEC). It ensures that this important information is publicly accessible through regulatory filings.

Does this filing provide any forward-looking guidance from AbbVie?

This 8-K filing itself does not contain forward-looking guidance. Such information would typically be found within the press release (Exhibit 99.1) or in subsequent investor calls and filings. Investors should carefully read the press release for any stated guidance or outlook.

ABBV 8-K: Earnings & Results

Q: Are there any other material events reported in this 8-K besides the financial results?

Based on the provided content, this 8-K filing is solely focused on the announcement of AbbVie's financial results for the fourth quarter and full year ended December 31, 2025. No other material events are indicated in this specific filing.

Summary

AbbVie Inc. (ABBV) has filed an 8-K report on February 4, 2026, primarily to furnish a press release detailing its financial results for the fourth quarter and full year ended December 31, 2025. While the filing itself does not contain the specific financial figures, it signals that key performance metrics, revenue figures, and profitability details have been made public through the attached press release. Investors should refer to Exhibit 99.1 for a comprehensive understanding of AbbVie's recent financial performance and its implications for the company's outlook.

Key Highlights

1AbbVie Inc. announced its financial results for Q4 and full year 2025 via a press release filed on February 4, 2026.
2The 8-K filing serves to formally submit the press release containing these results to the SEC.
3Investors can find detailed financial performance information, including revenue, earnings, and operational metrics, within the furnished press release (Exhibit 99.1).
4The filing indicates the company has met its reporting obligations for the period ended December 31, 2025.
5Key financial indicators for the full fiscal year 2025 are now publicly available.
6No other material events or disclosures are highlighted in this specific 8-K filing beyond the financial results announcement.

AbbVie Inc. 8-K Report, Financial Results (Feb 4, 2026)

Summary

Key Highlights

Frequently Asked Questions